Skip to main content

Table 4 Toxic and adverse effects in patients in the two study groups (According to NCI-CTCAE v3.0)

From: Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer

Parameter

Raltitrexed group (RT) nā€‰=ā€‰48

Normal saline group (NS) nā€‰=ā€‰43

I

II

III

IV

V

I

II

III

IV

V

WBC

3

2

1

0

0

3

2

0

0

0

Platelet count

2

2

0

0

0

3

2

0

0

0

Bleeding

0

0

0

0

0

0

0

0

0

0

Renal toxicity

3

0

0

0

0

3

0

0

0

0

Hepatotoxicity

5

1

0

0

0

4

1

0

0

0

Fever (postoperation >7 days)

0

0

0

0

0

0

0

0

0

0

Infection

5

0

0

0

0

6

0

0

0

0

Diarrhea

2

0

0

0

0

3

0

0

0

0

Vomiting

3

2

0

0

0

3

1

0

0

0

Constipation

4

1

0

0

0

5

1

0

0

0

Cardiac function

0

0

0

0

0

0

0

0

0

0

Pneumonia (X-ray)

2

0

0

0

0

2

0

0

0

0

Peripheral numbness

0

0

0

0

0

0

0

0

0

0

Allergic reaction

2

0

0

0

0

3

0

0

0

0

Abdominal ache (postoperation >7 days)

7

1

0

0

0

8

1

0

0

0

  1. NCI-CTCAE, National Cancer Institute common terminology criteria for adverse events; WBC, white blood cell.